Patents Represented by Attorney, Agent or Law Firm Susan E. Lingenfelter
  • Patent number: 8268311
    Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: September 18, 2012
    Assignee: Amgen Inc.
    Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
  • Patent number: 8263750
    Abstract: A method for purifying a protein using Protein A chromatography comprising a) absorbing the protein to Protein A immobilized on a solid support; b) removing contaminants by washing the immobilized Protein A containing the absorbed protein with a buffer comprising one or more chaotropic agents in combination with one or more hydrophobic modifiers and having a pH of at least 7.0; and c) eluting the protein from the Protein A immobilized on the solid support.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: September 11, 2012
    Assignee: Amgen Inc.
    Inventors: Abhinav A. Shukla, Peter Hinckley
  • Patent number: 8129167
    Abstract: ULBP4, a novel member of the ULBP family has been isolated and characterized. ULBP4 is a useful activator of immune effector cells, particularly of NK cells. Nucleic acids encoding ULBP4, vectors, and cells encoding the same are provided.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: March 6, 2012
    Assignee: Immunex Corporation
    Inventor: David J. Cosman
  • Patent number: 7807796
    Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.
    Type: Grant
    Filed: August 4, 2008
    Date of Patent: October 5, 2010
    Assignee: Immunex Corporation
    Inventors: David J Cosman, Jurgen Mullberg, William C Fanslow, III, Marek Z Kubin, Richard J Armitage
  • Patent number: 7695948
    Abstract: A metalloprotease that converts TNF-? from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: April 13, 2010
    Assignee: Immunex Corporation
    Inventors: Roy A. Black, Charles Rauch, Carl J. March, Douglas P. Cerretti
  • Patent number: 7285643
    Abstract: The invention is directed to purified and isolated novel murine and human kinase polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: October 23, 2007
    Assignee: Immunex Corporation
    Inventors: Timothy A. Bird, G. Duke Virca, Unja Martin, Dirk M. Anderson
  • Patent number: 7273609
    Abstract: The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF? inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF? inhibitors.
    Type: Grant
    Filed: August 18, 2006
    Date of Patent: September 25, 2007
    Assignee: Immunex Corporation
    Inventors: Kendall M. Mohler, Dauphine S. Barone, Mary K. Kennedy
  • Patent number: 7132264
    Abstract: This invention relates to Thypin, a new member of the human serpin polypeptide family, methods of making Thypin polypeptides and using these polypeptides to treat various medical disorders and to methods of screening for compounds that agonize or antagonize Thypin polypeptide activities.
    Type: Grant
    Filed: September 2, 2005
    Date of Patent: November 7, 2006
    Assignee: Immunex Corporation
    Inventors: Howard R. G. Clarke, Robert F. DuBose, Steven R. Wiley
  • Patent number: 7022690
    Abstract: Selected novel carboxylic acid substituted heterocycle compounds are effective for prophylaxis and treatment of inflammation, tissue degradation, cancer, fibrosis and related diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of inflamation, tissue degradation and related diseases. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: April 4, 2006
    Assignee: Amgen Inc.
    Inventors: Kevin Koch, Andreas Termin, John A. Josey
  • Patent number: 6627735
    Abstract: A mammalian islet cell antigen polypeptide involved in the development of insulin-dependent diabetes mellitus (IDDM) is disclosed. This islet cell antigen polypeptide, 1851, was found to contain regions of homology to the protein tyrosine phosphatase family. Methods for diagnosis and treatment, including use in immunoprecipitation assays and the induction of immune tolerance using the recombinant mammalian polypeptides and antibodies specific to mammalian islet cell antigen 1851 polypeptides are presented.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: September 30, 2003
    Assignee: ZymoGenetics, Inc.
    Inventors: Wayne Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, William A. Hagopian, James M. LaGasse
  • Patent number: 6617109
    Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.
    Type: Grant
    Filed: November 14, 2000
    Date of Patent: September 9, 2003
    Assignee: Corixa Corporation
    Inventors: Jiangchun Xu, John A. Stolk
  • Patent number: 6613515
    Abstract: Compositions and methods for the therapy and diagnosis of cancer, such as ovarian cancer, are disclosed. Compositions may comprise one or more ovarian carcinoma proteins, portions thereof, polynucleotides that encode such portions or antibodies or immune system cells specific for such proteins. Such compositions may be used, for example, for the prevention and treatment of diseases such as ovarian cancer. Polypeptides and polynucleotides as provided herein may further be used for the detection and monitoring of ovarian cancer.
    Type: Grant
    Filed: August 15, 2000
    Date of Patent: September 2, 2003
    Assignee: Corixa Corporation
    Inventors: Jiangchun Xu, John A. Stolk
  • Patent number: 6566499
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zsig37, a novel member of the family of proteins bearing a collagen-like domain and a globular domain. The polypeptides, and polynucleotides encoding them, are involved in dimerization or oligomerization and may be used in the study thereof. The present invention also includes antibodies to the zsig37 polypeptides.
    Type: Grant
    Filed: February 17, 2000
    Date of Patent: May 20, 2003
    Assignee: ZymoGenetics, Inc.
    Inventor: Paul O. Sheppard
  • Patent number: 6537555
    Abstract: Compounds and methods for the diagnosis and treatment of HSV infection are provided. The compounds comprise polypeptides that contain at least one antigenic portion of an HSV polypeptide and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits are also provided comprising such polypeptides and/or DNA sequences and a suitable detection reagent for the detection of HSV infection in patients and in biological samples.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: March 25, 2003
    Assignee: Corixa Corporation
    Inventors: Nancy A. Hosken, Craig H. Day, Davin C. Dillon, Patrick McGowan, Paul R. Sleath
  • Patent number: 6482612
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zsig39, a novel member of the family of proteins bearing a collagen-like domain and a globular domain. The polypeptides, and polynucleotides encoding them, are involved in dimerization or oligomerization and may be used in the study thereof. The present invention also includes antibodies to the zsig39 polypeptides.
    Type: Grant
    Filed: October 10, 2000
    Date of Patent: November 19, 2002
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Jacqueline M. Humes
  • Patent number: 6420525
    Abstract: Novel ZGCL-1 transcription factor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides, agonists and antagonists may be used within methods for promoting the proliferation and/or differentiation of testis cells, and may also be used in the development of male-specific contraceptives and infertility treatments.
    Type: Grant
    Filed: August 19, 1998
    Date of Patent: July 16, 2002
    Assignee: ZymoGenetics, Inc.
    Inventors: David P. Yee, Theresa A. Deisher
  • Patent number: 6391917
    Abstract: Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin receptor activity.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: May 21, 2002
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles R. Petrie, Patricia A. McKernan, Emma E. Moore, John M. Ostresh, Jean-Philippe Meyer, Richard A. Houghten, Clemencia Pinilla
  • Patent number: 6372889
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for ZTMPO-1, a novel soluble protein with homology to emerin and the thymopoietins. The polypeptides, and polynucleotides encoding them are useful for modulating cellular proliferation and differentiation and may be used for diagnostic purposes. The present invention also includes antibodies to the ZTMPO-1 polypeptides.
    Type: Grant
    Filed: April 19, 1999
    Date of Patent: April 16, 2002
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Darrell C. Conklin, Theresa M. Farrah, Mark F. Maurer, Angelika Grossmann
  • Patent number: 6355788
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zfsta2, a novel member of the follistatin family. The polypeptides, and polynucleotides encoding them are useful for binding to members of the TGF-&bgr; family and mediating central nervous system, reproductive, hematopoietic and bone-related activities. The present invention also includes antibodies to the zfsta2 polypeptides.
    Type: Grant
    Filed: October 5, 1999
    Date of Patent: March 12, 2002
    Assignee: ZymoGenetics, Inc.
    Inventors: Darrell C. Conklin, Jeff L. Ellsworth
  • Patent number: 6300093
    Abstract: A mammalian islet cell antigen polypeptide involved in the development of insulin-dependent diabetes mellitus (IDDM) is disclosed. This islet cell antigen polypeptide, 1851, was found to contain regions of homology to the protein tyrosine phosphatase family. Methods for diagnosis and treatment, including use in immunoprecipitation assays and the induction of immune tolerance using the recombinant mammalian polypeptides and antibodies specific to mammalian islet cell antigen 1851 polypeptides are presented.
    Type: Grant
    Filed: March 5, 1997
    Date of Patent: October 9, 2001
    Assignees: ZymoGenetics, Inc., University of Washington
    Inventors: Wayne Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, William A. Hagopian, James M. LaGasse